Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « drugs »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
drug < drugs < dry  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 83.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000005 (2020) Tadeusz Płusa[Options for controlling new Corona virus infection - 2019-nCoV].
000006 (2020) Anna Jakubczyc ; Claus Neurohr[Interstitial lung disease in rheumatic diseases - new therapeutic approaches].
000034 (2020) Angelika Batta ; Bhupinder Singh Kalra ; Raj KhirasariaTrends in FDA drug approvals over last 2 decades: An observational study
000042 (2020) Prakhar Vijayvargiya [États-Unis] ; Zerelda Esquer Garrigos [États-Unis] ; Natalia E. Castillo Almeida [États-Unis] ; Pooja R. Gurram [États-Unis] ; Ryan W. Stevens [États-Unis] ; Raymund R. Razonable [États-Unis]Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
000047 (2020) María Martín-L Pez [Espagne] ; Eliseo Albert [Espagne] ; Mario Fernández-Ruiz [Espagne] ; Isidoro González-Álvaro [Espagne] ; Esther Rodríguez [Espagne] ; José M. Aguado [Espagne] ; David Navarro [Espagne] ; José L. Pablos [Espagne]Torque teno virus viremia in patients with chronic arthritis: Influence of biologic therapies.
000077 (2020) Lei Li [République populaire de Chine] ; Ranran Li [République populaire de Chine] ; Zhixiong Wu [République populaire de Chine] ; Xianghong Yang ; Mingyan Zhao [République populaire de Chine] ; Jiao Liu [République populaire de Chine] ; Dechang Chen [République populaire de Chine]Therapeutic strategies for critically ill patients with COVID-19
000079 (2020) Caterina Vacchi [Italie] ; Marco Sebastiani [Italie] ; Giulia Cassone [Italie] ; Stefania Cerri [Italie] ; Giovanni Della Casa [Italie] ; Carlo Salvarani [Italie] ; Andreina Manfredi [Italie]Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review
000081 (2020) Francisco Vílchez-Oya [Espagne] ; Julia María Sánchez-Schmidt [Espagne] ; Anna Agustí [Espagne] ; Ana Pros [Espagne]The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review.
000082 (2020) Eun-Jung Park [Corée du Sud] ; Hyungjin Kim [Corée du Sud] ; Seung Min Jung [Corée du Sud] ; Yoon-Kyoung Sung [Corée du Sud] ; Han Joo Baek [Corée du Sud] ; Jisoo Lee [Corée du Sud]The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
000083 (2020) Wen Zhang [République populaire de Chine] ; Yan Zhao [République populaire de Chine] ; Fengchun Zhang [République populaire de Chine] ; Qian Wang [République populaire de Chine] ; Taisheng Li [République populaire de Chine] ; Zhengyin Liu [République populaire de Chine] ; Jinglan Wang [République populaire de Chine] ; Yan Qin [République populaire de Chine] ; Xuan Zhang [République populaire de Chine] ; Xiaowei Yan [République populaire de Chine] ; Xiaofeng Zeng [République populaire de Chine] ; Shuyang Zhang [République populaire de Chine]The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China
000089 (2020) Jacob J. Adashek [États-Unis] ; Shumei Kato [États-Unis] ; Scott M. Lippman [États-Unis] ; Razelle Kurzrock [États-Unis]The paradox of cancer genes in non-malignant conditions: implications for precision medicine
000092 (2020) Camilla Br Dsgaard Nielsen [Danemark] ; Christian Nielsen [Danemark] ; Mads Nybo [Danemark] ; S Ren Andreas Just [Danemark] ; Pernille Just Vinholt [Danemark]The in vitro effect of antirheumatic drugs on platelet function.
000099 (2020) Carlo Perricone [Italie] ; Paola Triggianese [Italie] ; Elena Bartoloni [Italie] ; Giacomo Cafaro [Italie] ; Angelo F. Bonifacio [Italie] ; Roberto Bursi [Italie] ; Roberto Perricone [Italie] ; Roberto Gerli [Italie]The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
000118 (2020) Gregory S. Calip [États-Unis] ; Pritesh R. Patel [États-Unis] ; Karen Sweiss [États-Unis] ; Zhaoju Wu [États-Unis] ; Jifang Zhou [États-Unis] ; Alemseged A. Asfaw [États-Unis] ; Sruthi Adimadhyam [États-Unis] ; Todd A. Lee [États-Unis] ; Brian C-H Chiu [États-Unis]Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma.
000128 (2020) Sophie Testa [Italie] ; Oriana Paoletti [Italie] ; Matteo Giorgi-Pierfranceschi [Italie] ; Angelo Pan [Italie]Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
000139 (2020) Chayma Ladhari [France] ; Pierre Le Blay [France] ; Thierry Vincent [France] ; Ahmed Larbi [France] ; Emma Rubenstein [France] ; Rosanna Ferreira Lopez [France] ; Christian Jorgensen [France] ; Yves-Marie Pers [France]Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
000140 (2020) Yusho Ishii [Japon] ; Hiroshi Fujii [Japon] ; Koichiro Sugimura [Japon] ; Tsuyoshi Shirai [Japon] ; Yosuke Hoshi [Japon] ; Yoko Fujita [Japon] ; Yuko Shirota [Japon] ; Tomonori Ishii [Japon] ; Hiroaki Shimokawa [Japon] ; Hideo Harigae [Japon]Successful Treatment of Pulmonary Arterial Hypertension in Systemic Sclerosis with Anticentriole Antibody
000141 (2020) Adam Amlani [Canada] ; Claire Barber [Canada] ; Aurore Fifi-Mah [Canada] ; Jose Monzon [Canada]Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature.
000143 (2020) Eduardo Mysler [Argentine] ; Mario H. Cardiel [Mexique] ; Ricardo M. Xavier [Brésil] ; Alejandra L Pez ; Allan Ramos-Esquivel [Costa Rica]Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study.
000148 (2020) Some drugs for COVID-19.
000151 (2020) Joanna Wai Yee Leong [Singapour] ; Peter P. Cheung [Singapour] ; Sajeewani Dissanayake [Singapour] ; Warren Weng Seng Fong [Singapour] ; Keng Hong Leong [Singapour] ; Ying Ying Leung [Singapour] ; Anita Yee Nah Lim [Singapour] ; Nai Lee Lui [Singapour] ; Mona Manghani [Singapour] ; Amelia Santosa [Singapour] ; Melonie Kannamma Sriranganathan [Singapour] ; Ernest Suresh [Singapour] ; Teck Choon Tan [Singapour] ; Gim Gee Teng [Singapour] ; Manjari Lahiri [Singapour]Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "drugs" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "drugs" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    drugs
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021